Aspira Women's Health Inc. (AWHL): Nasdaq/NYSE listing notice — Aspira Women's Health resolves Nasdaq listing violation by amending warrants; compliance regained but risk remains

Aspira Women's Health Inc.

Received Nasdaq notice Feb 11, 2025 for violating Rule 5635(c) by issuing shares/warrants below market value without shareholder approval.
Amended warrants same day to prohibit exercise until shareholder approval, regaining compliance with Nasdaq.
Private placement involved 1,264,739 shares and warrants at $1.53/unit; market value per unit was $1.595.
Company cautions there is no guarantee its common stock will remain listed on Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5635(c)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: shareholders
Rules: 5635(c)

Exact text from the filing

February 11, 2025, the Company received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) that based on the closing bid price per share immediately preceding entering into a binding agreement to

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding other (rules 5635(c)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5635(c)

Exact text from the filing

February 11, 2025, the Company received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) that based on the closing bid price per share immediately preceding entering into a binding agreement to issue the securities for the Private Placement of $1.47 per share plus $0.125 attributable to the value of the warrants, the market value of the transaction for purposes of Listing Rule 5625(c) was $1.595. Since the shares and warrants sold in the private placement were issued below the market value, and the Company failed to obtain shareholder approval, the Company violated Li

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-006890

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.